Novigenix Wins the 2021 Felix Burda Award in Medicine & Science

– Category ‘Innovation in Immuno-Transcriptomics for the Early Detection of Colon Cancer’

– Award recognizes outstanding innovation and effectiveness in early cancer detection

LAUSANNE, Switzerland, July 22, 2021 / PRNewswire / – Novigenix SA, a leading Swiss biotechnology company that develops and markets precision immunotranscriptomics oncology solutions, today announced the Felix Burda Award 2021 in the Medicine & Science category.

Novigenix logo

Novigenix logo

The Felix Burda The award was launched in 2003 Munich, Germany the Felix Burda Foundation to honor individuals and teams who have made a contribution to the prevention and early detection of colon cancer. The foundation has appointed an independent jury of leading figures from science and practice to guide the evaluation of the nominations and the selection of the winners of the award in the Medicine & Science category.

DR. Berndt Birkner, Member of Felix Burda Prize jury and chairman of the working group for medical quality management in the professional association of German internists said:

“Like other human tumors, colon cancer triggers a cellular immune response from white blood cells in the circulation and in the bone marrow. These white blood cells, which are used for tumorous angiogenesis and metastasis, express biomarkers that can be detected with special mRNA in the blood. In this way it would of course be easier for a doctor to diagnose changes in the intestine. The judges and I hope that this new solution will fuel the discussion about the type of early detection in Germany. ”

professor Christoph Beglinger, former head physician at the Clinic for Gastroenterology and Hepatology, University Hospital Basel, adds:

“Colon cancer usually develops from benign polyps that develop into cancer in about 10 years. In order to detect colon cancer in its early stages, medical guidelines currently recommend stool examinations or a colonoscopy. Detecting colon cancer by questioning the patient’s immune cells is a fascinating development that opens up completely new possibilities for colorectal cancer prevention. ”

DR. Brian Hashemi, Executive Chairman of Novigenix, said:

“We are honored for this prestigious award and the recognition of our decades of work that has led to our advanced precision oncology platform that utilizes the mRNA signatures of patients’ immune cells.”

for disease detection and therapy optimization. mRNA therapeutics have already played an important role in COVID vaccine development, and Novigenix’s mRNA / immunotranscriptomic platform can help accelerate disease detection and support the development of new therapeutic solutions. I would like to acknowledge the work of the Novigenix scientific team and thank the thousands of patients, researchers and prescribers who have made valuable contributions to the development of this life-saving technology. ‘

About colon cancer

Colon cancer is the second leading cause of cancer death and the number of cases is expected to increase over the next two decades due to the aging population. This high mortality rate is due to the silent development of the disease, as symptoms do not appear until later stages, when the therapeutic response is poor. If detected early, colon cancer is very curable and can be prevented by removing precursor lesions known as adenomatous polyps.

About Novigenix

Novigenix is ​​a precision medicine biotechnology company that enables a new understanding of the human host’s immune response to cancer. The company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in the diagnosis and treatment of cancer patients and lead to significant improvements in healthcare. Novigenix’s unique immuno-transcriptome platform enables accelerated identification of disease-specific mRNA signatures from immune cells, which, when combined with machine learning and predictive algorithms, provide precision solutions for disease detection and response to therapeutic interventions. More information is available at

Logo –


Valentin Matillon, President and Chief Business Officer
T: +41 21 552 07 30

LifeSpring Life Sciences Communication, Amsterdam, Netherlands
Leon Melens
T: +31 6 538 16 427



View original content to download multimedia:–science-301338940.html

SOURCE Novigenix

مقالات ذات صلة

اترك تعليقاً

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *

زر الذهاب إلى الأعلى